LIXTE Biotechnology Announces ~$16.57M Registered Direct Offering, Selling ~2.625M Shares And Pre-Funded Warrants At A Combined Price Of $6.31
LIXTE Biotechnology To Seek Strategic Acquisition Partner For Its Clinical Stage Pharmaceutical And Med-Tech Business
Lixte Biotech Hldgs Q1 EPS $(0.18) Up From $(0.29) YoY
Lixte Biotech Hldgs Q4 EPS $(0.34) Down From $(0.27) YoY
LIXTE Biotechnology (LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary
LIXTE Biotechnology (LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy
LIXTE Biotechnology (LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment
LIXTE Biotechnology (LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment
Improving the Odds: How LIXTE Biotechnology (LIXT) Is Working to Make Cancer Therapies More Effective
LIXTE Biotechnology Holdings (LIXT) Advances a Novel Approach to Enhancing Cancer Therapy
LIXTE Biotechnology Holdings (LIXT) Sponsors Good Health Mind, Body and Soul Summit
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
IBN Initiates Coverage of LIXTE Biotechnology Holdings Inc.
LIXTE Biotechnology Holdings (LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK
Lixte Biotechnology Enters Share Exchange Agreement, Swapping 2,700 Series C Preferred Shares For 700,000 Common Shares And ~20% Of Outstanding Shares For Subsidiary Liora Technologies Europe
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
LIXTE Biotechnology Expands Collaboration With University Of Texas MD Anderson Cancer Center And GSK On Ongoing Clinical Trial With LIXTE's Proprietary Compound, LB-100, To Treat Ovarian Clear Cell Cancer
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
